Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1992 Feb;215(2):157–165. doi: 10.1097/00000658-199202000-00011

Enhancement of interleukin-2 immunotherapy with L-arginine.

M D Lieberman 1, K Nishioka 1, H P Redmond 1, J M Daly 1
PMCID: PMC1242404  PMID: 1546902

Abstract

Nutrient substrates have been shown to enhance cell-mediated immunity, but their role as adjuvants to immunotherapy has not been previously determined. This study evaluated L-arginine as an essential substrate for optimal generation of lymphokine-activated killer (LAK) cells. This experiment also assessed supplemental dietary L-arginine as a means to potentiate the host antitumor response to interleukin-2 (IL-2) in a murine neuroblastoma (NRB) model. A/J mice received 1% arginine or isonitrogenous 1.7% glycine in addition to a regular diet 14 days before subcutaneous inoculation with C1300 NRB cells. Twenty-four hours later, animals received low (1 x 10(6) U/kg three times a day) or high (3 x 10(6) U/kg three times a day) doses of IL-2 or saline intraperitoneally for 4 days. On days 4 and 10 post-C1300 NRB inoculation, mice were killed for assessment of natural killer cell and tumor specific cytotoxicity. Remaining animals were followed for tumor incidence, tumor growth, and duration of host survival. Interleukin-2 therapy in mice receiving dietary arginine compared with those receiving glycine resulted in significantly augmented natural killer cell cytotoxicity (day 4) and generation of specific tumoricidal mechanisms (day 10). The addition of dietary arginine to low-dose IL-2 therapy significantly diminished C1300 NRB engraftment (p less than 0.05) and growth (p less than 0.001) and prolonged the duration of host survival (p less than 0.05) compared with the glycine treatment group. In vitro studies demonstrated that L-arginine is an essential substrate for optimal generation of LAK cells. Thus, supplemental dietary L-arginine enhances lymphocyte cytotoxic mechanisms and potentiates IL-2 immunotherapy.

Full text

PDF
157

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. W., Saito H., Trocki O., Ogle C. K. The importance of lipid type in the diet after burn injury. Ann Surg. 1986 Jul;204(1):1–8. doi: 10.1097/00000658-198607000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):227–238. doi: 10.1177/0148607186010002227. [DOI] [PubMed] [Google Scholar]
  3. Daly J. M., Reynolds J., Thom A., Kinsley L., Dietrick-Gallagher M., Shou J., Ruggieri B. Immune and metabolic effects of arginine in the surgical patient. Ann Surg. 1988 Oct;208(4):512–523. doi: 10.1097/00000658-198810000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ettinghausen S. E., Lipford E. H., 3rd, Mulé J. J., Rosenberg S. A. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol. 1985 Aug;135(2):1488–1497. [PubMed] [Google Scholar]
  5. Fanslow W. C., Kulkarni A. D., Van Buren C. T., Rudolph F. B. Effect of nucleotide restriction and supplementation on resistance to experimental murine candidiasis. JPEN J Parenter Enteral Nutr. 1988 Jan-Feb;12(1):49–52. doi: 10.1177/014860718801200149. [DOI] [PubMed] [Google Scholar]
  6. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  7. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  8. Gillis S., Smith K. A. Long term culture of tumour-specific cytotoxic T cells. Nature. 1977 Jul 14;268(5616):154–156. doi: 10.1038/268154a0. [DOI] [PubMed] [Google Scholar]
  9. Gottschlich M. M., Jenkins M., Warden G. D., Baumer T., Havens P., Snook J. T., Alexander J. W. Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN J Parenter Enteral Nutr. 1990 May-Jun;14(3):225–236. doi: 10.1177/0148607190014003225. [DOI] [PubMed] [Google Scholar]
  10. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hibbs J. B., Jr, Vavrin Z., Taintor R. R. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol. 1987 Jan 15;138(2):550–565. [PubMed] [Google Scholar]
  12. Jones B. N., Gilligan J. P. o-Phthaldialdehyde precolumn derivatization and reversed-phase high-performance liquid chromatography of polypeptide hydrolysates and physiological fluids. J Chromatogr. 1983 Aug 26;266:471–482. doi: 10.1016/s0021-9673(01)90918-5. [DOI] [PubMed] [Google Scholar]
  13. Karpeh M. S., Kehne J. A., Choi S. H., Ziegler M. M. Tumor immunogenicity, nutritional repletion, and cancer. Surgery. 1987 Aug;102(2):283–290. [PubMed] [Google Scholar]
  14. LEVY H. M., MONTANEZ G., FEAVER E. R., MURPHY E. A., DUNN M. S. Effect of arginine on tumor growth in rats. Cancer Res. 1954 Mar;14(3):198–200. [PubMed] [Google Scholar]
  15. Mulé J. J., Shu S., Schwarz S. L., Rosenberg S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984 Sep 28;225(4669):1487–1489. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  16. Mulé J. J., Yang J. C., Afreniere R. L., Shu S. Y., Rosenberg S. A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol. 1987 Jul 1;139(1):285–294. [PubMed] [Google Scholar]
  17. Mulé J. J., Yang J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol. 1986 May 15;136(10):3899–3909. [PubMed] [Google Scholar]
  18. Ortaldo J. R., Mason A., Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med. 1986 Oct 1;164(4):1193–1205. doi: 10.1084/jem.164.4.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Papa M. Z., Yang J. C., Vetto J. T., Shiloni E., Eisenthal A., Rosenberg S. A. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 1988 Jan 1;48(1):122–129. [PubMed] [Google Scholar]
  20. Pegg A. E., McCann P. P. Polyamine metabolism and function. Am J Physiol. 1982 Nov;243(5):C212–C221. doi: 10.1152/ajpcell.1982.243.5.C212. [DOI] [PubMed] [Google Scholar]
  21. Reynolds J. V., Daly J. M., Shou J., Sigal R., Ziegler M. M., Naji A. Immunologic effects of arginine supplementation in tumor-bearing and non-tumor-bearing hosts. Ann Surg. 1990 Feb;211(2):202–210. doi: 10.1097/00000658-199002000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reynolds J. V., Daly J. M., Zhang S., Evantash E., Shou J., Sigal R., Ziegler M. M. Immunomodulatory mechanisms of arginine. Surgery. 1988 Aug;104(2):142–151. [PubMed] [Google Scholar]
  23. Robb R. J., Munck A., Smith K. A. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med. 1981 Nov 1;154(5):1455–1474. doi: 10.1084/jem.154.5.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rosenberg S. A., Mulé J. J., Spiess P. J., Reichert C. M., Schwarz S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985 May 1;161(5):1169–1188. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  27. Rosenstein M., Yron I., Kaufmann Y., Rosenberg S. A. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984 May;44(5):1946–1953. [PubMed] [Google Scholar]
  28. Rudolph F. B., Kulkarni A. D., Schandle V. B., Van Buren C. T. Involvement of dietary nucleotides in T lymphocyte function. Adv Exp Med Biol. 1984;165(Pt B):175–178. doi: 10.1007/978-1-4757-0390-0_35. [DOI] [PubMed] [Google Scholar]
  29. Saito H., Trocki O., Wang S. L., Gonce S. J., Joffe S. N., Alexander J. W. Metabolic and immune effects of dietary arginine supplementation after burn. Arch Surg. 1987 Jul;122(7):784–789. doi: 10.1001/archsurg.1987.01400190050010. [DOI] [PubMed] [Google Scholar]
  30. Tachibana K., Mukai K., Hiraoka I., Moriguchi S., Takama S., Kishino Y. Evaluation of the effect of arginine-enriched amino acid solution on tumor growth. JPEN J Parenter Enteral Nutr. 1985 Jul-Aug;9(4):428–434. doi: 10.1177/0148607185009004428. [DOI] [PubMed] [Google Scholar]
  31. Trinchieri G., Aden D. P., Knowles B. B. Cell-mediated cytotoxicity to SV40-specific tumour-associated antigens. Nature. 1976 May 27;261(5558):312–314. doi: 10.1038/261312a0. [DOI] [PubMed] [Google Scholar]
  32. Watson J. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med. 1979 Dec 1;150(6):1510–1519. doi: 10.1084/jem.150.6.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES